How does medical confidentiality work in Sweden and Germany?
Medical confidentiality is the rule in Sweden and Germany. But it has set limits. Sweden has one law for public care and one for private care. German law guards secrets told to a doctor. A separate health law calls for reports about a set list of diseases.
What is the confidentiality rule in Swedish public care?
OSL 25 kap. 1 § sets the rule for public health care. It applies secrecy to a person's health status. It also covers other personal circumstances. Its exception requires clarity that disclosure will not harm the person or a close relative.
"Sekretess gäller inom hälso- och sjukvården"
That wording makes secrecy the starting position. The section does not promise that disclosure can never occur.
Primary source, checked 21 August 2026: Offentlighets- och sekretesslag (2009:400), 25 kap. 1 §.
Does private Swedish care use the same rule?
PSL 6 kap. 12 § sets the rule for private health care. It bars health-care staff from sharing what they learn about a person's health without authorisation. It also covers other personal circumstances.
"får inte obehörigen röja"
The same section says that fulfilling an information duty created by law or regulation is not unauthorised disclosure. It also points public-sector activity back to the Public Access to Information and Secrecy Act.
The public and private provisions therefore do not use the same test. The private provision does not list every statutory information duty that may apply in a particular setting.
Primary source, checked 21 August 2026: Patientsäkerhetslag (2010:659), 6 kap. 12 §.
What does German medical confidentiality protect?
Section 203(1) of the German Criminal Code protects a secret entrusted to a doctor. It also covers a secret learned in that professional role. Both protections apply against unauthorised disclosure. The provision uses the word unbefugt, meaning without authorisation.
"Wer unbefugt ein fremdes Geheimnis ... offenbart"
The qualifier matters because the protection is not a promise against every disclosure. A separate statute can create a defined reporting duty.
Primary source, checked 21 August 2026: Strafgesetzbuch § 203.
What health information is reported in Germany?
German health law has more than one way to report a disease or test result. The path depends on what was found.
| What is reported | Reporting form | Who reports | Destination and timing |
|---|---|---|---|
Acute viral hepatitis under IfSG § 6(1)(1)(e) | By name | The diagnosing doctor under § 8(1)(1) | The local Gesundheitsamt within 24 hours under § 9(3)-(4) |
Hepatitis B or C virus detection under § 7(1)(21)-(22) | By name | The head of the testing laboratory under § 8(1)(2) | The local Gesundheitsamt within 24 hours under § 9(2)-(4) |
HIV detection under § 7(3)(2) | Without the person's name | The head of the testing laboratory under § 8(1)(2) | The Robert Koch Institute within two weeks under § 10(2) |
A named report under IfSG § 9 has the person's name. It also has the person's home address. The HIV report under IfSG § 10(2) uses a case-based pseudonym. It includes sex. It includes the month and year of birth. It includes the first three postcode digits.
Sections 6 and 7 list diseases and germ test results. They do not list peptide use on its own.
Primary sources, checked 21 August 2026: IfSG § 6, § 7, § 8, § 9 and § 10.
What did research measure about seeking treatment?
In PMID 24713416, the sample had 366 men. Recruitment occurred across England and Wales. They injected image- and performance-enhancing drugs. The questionnaire addressed injection-site problems. The paper is by Hope et al.
The Health Protection Agency ran the survey. The paper says the agency was funded through the Department of Health. The paper says the work had no specific grant.
In table 3 of PMID 24713416, each man could name more than one source of care. In PMID 24713416, the redness percentages use 27 as their denominator. In the same table, the abscess percentages use 19 as their denominator.
Table 3 result, PMID 24713416 | Redness, tenderness or swelling | Abscess, sore or open wound |
|---|---|---|
| Reported the symptom | 155 men | 25 men |
| Ever had treatment | 27 of 155 (17%) | 19 of 25 (76%) |
| General practitioner | 16 of 27 (59%) | 6 of 19 (32%) |
| Emergency department or walk-in clinic | 13 of 27 (48%) | 9 of 19 (47%) |
| Self-treatment | 13 of 27 (48%) | 5 of 19 (26%) |
| Needle and syringe programme | 6 of 27 (22%) | 1 of 19 (5%) |
| Other source | 6 of 27 (22%) | 0 of 19 (0%) |
The authors say some men may have stayed away due to concern about sharing drug use. The study did not prove why.
The study drew men through health services. In PMID 24713416, 274 of 366 men (75%) had used a needle and syringe programme before. The authors say they could not measure how well the sample stood for the group.
The answers were self-reported. The study did not treat peptide users as their own group. It did not test what doctors later shared.
Primary source, checked 21 August 2026: Hope et al., Epidemiology and Infection, PMID 24713416, PMCID PMC9206780.
What can this page answer for one appointment?
These laws set the main rule and some clear report paths. They cannot tell you what will happen in each visit.
We did not map all duties for private Swedish care. We did not review each work code or clinic rule. So this page gives the law we read without a promise about one visit.
For the health signs that make an appointment useful, see when to get medical help. For the evidence behind contamination and infection risk, see sterility and infection.
The shared evidence-question overview connects this appointment question to related vial, test and symptom evidence.